Alexa Fluor® 647 anti-mouse CD64 (FcγRI)-上海雅吉生物科技有限公司

规格	价格	库存
25µg	￥ 1806	1

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Mouse

Immunogen

BALB/c mouse FcγRI-human IgG Fc fusion protein.

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography and conjugated with Alexa Fluor? 647 under optimal conditions.

Concentration

0.5 mg/ml

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested
SB - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

* Alexa Fluor? 647 has a maximum emission of 668 nm when it is excited at 633 nm / 635 nm.

Alexa Fluor? and Pacific Blue? are trademarks of Life Technologies Corporation.

View full statement regarding label licenses

Excitation Laser

Red Laser (633 nm)

Application Notes

The X54-5/7.1 antibody reacts with mouse strains carrying CD64a and b alleles but not CD64d. X54-5/7.1 recognizes a conformational determinant formed between domains 2 and 3. Additional reported application (for relevant formats) include: immunoprecipitation¹, and spatial biology (IBEX)^5,6. Clone X54-5/7.1 is not found to be useful for Western blots¹.

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References (PubMed link indicates BioLegend citation)